II期和III期结肠癌的辅助治疗：国际胃肠道肿瘤学会共识报告
Adjuvant Therapy for Stage II and III Colon Cancer: Consensus Report of the International Society of Gastrointestinal Oncology.
作者信息
Marshall John L, Haller Daniel G, de Gramont Aimery, Hochster Howard S, Lenz Heinz-Josef, Ajani Jaffer A, Goldberg Richard M
机构信息
Departments of Medicine and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC.
出版信息
Gastrointest Cancer Res. 2007 Jul;1(4):146-54.
Chemotherapy agents available for the treatment of stage II and stage III colon cancer have changed substantially since the 1992 National Institutes of Health consensus report recommended that all stage III patients routinely receive adjuvant treatment with 5-fluorouracil/levamisole. Subsequent trials demonstrated superiority of 5-fluorouracil/leucovorin over 5-fluorouracil/levamisole in the adjuvant setting, and the recent addition of oxaliplatin to this regimen has further improved disease-free survival. While stage III colon cancer patients are routinely treated, the use of adjuvant chemotherapy in patients with stage II disease is still a subject of debate. Many trials that are assessing the potential role of biologics in the adjuvant setting will soon be completed. However, identifying molecular prognostic markers that accurately select patients with stage II or III cancers who are at risk of recurrence would be essential to select and individualize therapy.
自1992年美国国立卫生研究院的共识报告建议所有III期患者常规接受5-氟尿嘧啶/左旋咪唑辅助治疗以来，可用于治疗II期和III期结肠癌的化疗药物已发生了很大变化。随后的试验表明，在辅助治疗中，5-氟尿嘧啶/亚叶酸钙优于5-氟尿嘧啶/左旋咪唑，并且最近在该方案中加入奥沙利铂进一步改善了无病生存期。虽然III期结肠癌患者常规接受治疗，但II期疾病患者辅助化疗的使用仍是一个有争议的话题。许多评估生物制剂在辅助治疗中潜在作用的试验即将完成。然而，识别能够准确筛选出有复发风险的II期或III期癌症患者的分子预后标志物对于选择和个体化治疗至关重要。
Zotero 插件